24.06.2015 • NewsDede Willamsprescriptionprofits

Americans Blame Drugmakers for High Prices

© Nikolai Sorokin - Fotolia.com
© Nikolai Sorokin - Fotolia.com

Americans are far more likely to blame pharmaceutical companies for high prescription medication costs than their health insurers, a recent poll has found. Of the 1,200 adults interviewed by the Kaiser Family Foundation’s researchers for the June Kaiser Health Tracking Poll, around three-quarters said the cost of prescription drug costs was unreasonable, but only10% of those responding blamed the high prices on co-pays demanded by their insurance company.

A similar majority said drug profits were a major factor in prescription prices, and 87% approved of enabling the Medicare program to negotiate prices with producers.

At the same time, over 70% of the poll’s respondents said they thought insurers should always pay for an expensive drug recommended by a doctor when no lower-cost alternative exists.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
06.03.2025 • News

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.